Search Results - "Wang, Reena"

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2) by Fleischmann, Roy M, van der Heijde, Désirée, Strand, Vibeke, Atsumi, Tatsuya, McInnes, Iain B, Takeuchi, Tsutomu, Taylor, Peter C, Bracher, Marguerite, Brooks, David, Davies, John, Goode, Christopher, Gupta, Anubha, Mukherjee, Sumanta, O'Shea, Ciara, Saurigny, Didier, Schifano, Lorrie A, Shelton, Celia, Smith, Julia E, Wang, Millie, Wang, Reena, Watts, Sarah, Weinblatt, Michael E

“…To investigate the efficacy and safety of otilimab, an antigranulocyte-macrophage colony-stimulating factor antibody, in patients with active rheumatoid…”
Get more information

Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3) by Taylor, Peter C, Weinblatt, Michael E, McInnes, Iain B, Atsumi, Tatsuya, Strand, Vibeke, Takeuchi, Tsutomu, Bracher, Marguerite, Brooks, David, Davies, John, Goode, Christopher, Gupta, Anubha, Mukherjee, Sumanta, O'Shea, Ciara, Saurigny, Didier, Schifano, Lorrie A, Shelton, Celia, Smith, Julia E, Wang, Millie, Wang, Reena, Watts, Sarah, Fleischmann, Roy M

“…To investigate the efficacy and safety of otilimab, an anti-granulocyte-macrophage colony-stimulating factor antibody, in patients with active rheumatoid…”
Get more information

Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti‐CD28 Domain Antibody Antagonist in Healthy Subjects by Shi, Rong, Honczarenko, Marek, Zhang, Sean, Fleener, Catherine, Mora, Johanna, Lee, Sun Ku, Wang, Reena, Liu, Xiaoni, Shevell, Diane E., Yang, Zheng, Wang, Haiqing, Murthy, Bindu

“…We report pharmacokinetics, pharmacodynamics, and safety of a novel anti‐CD28 domain antibody antagonist (lulizumab pegol) in healthy subjects following…”
Get full text

Pharmacokinetics and Pharmacodynamics of Atazanavir in HIV-1-Infected Children Treated With Atazanavir Powder and Ritonavir: Combined Analysis of the PRINCE-1 and -2 Studies by Sevinsky, Heather, Zaru, Luna, Wang, Reena, Xu, Xiaohui, Pikora, Cheryl, Correll, Todd A, Eley, Timothy

“…BACKGROUND:Two clinical studies (PRINCE-1 and -2) in HIV-1-infected children assessed the safety, efficacy and pharmacokinetics of dual nucleos(t)ide reverse…”
Get full text

A Review of Daclatasvir Drug–Drug Interactions by Garimella, Tushar, You, Xiaoli, Wang, Reena, Huang, Shu-Pang, Kandoussi, Hamza, Bifano, Marc, Bertz, Richard, Eley, Timothy

“…The treatment of hepatitis C virus (HCV) infection has been revolutionized in recent years by the development of direct-acting antiviral regimens that do not…”
Get full text

Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment by Garimella, Tushar, Wang, Reena, Luo, Wen-Lin, Hwang, Carey, Sherman, Diane, Kandoussi, Hamza, Marbury, Thomas C, Alcorn, Harry, Bertz, Richard, Bifano, Marc

“…Daclatasvir (DCV) is a pangenotypic inhibitor of the HCV NS5A replication complex approved in Japan and Europe for combination treatment of HCV. AI444-063 was…”
Get more information

A randomized trial in healthy subjects to assess the bioequivalence of an atazanavir/cobicistat fixed-dose combination tablet versus administration as separate agents by Sevinsky, Heather, Tao, Xiaolu, Wang, Reena, Ravindran, Palanikumar, Sims, Karen, Xu, Xiaohui, Jariwala, Navin, Bertz, Richard

“…Cobicistat (COBI) is an alternative pharmacoenhancer to ritonavir. A fixed-dose combination (FDC) tablet containing atazanavir (ATV) and COBI has been…”
Get more information

Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti-CD28 Domain Antibody Antagonist in Healthy Subjects: Novel Anti-CD28 Domain Antibody Antagonist by Shi, Rong, Honczarenko, Marek, Zhang, Sean, Fleener, Catherine, Mora, Johanna, Lee, Sun Ku, Wang, Reena, Liu, Xiaoni, Shevell, Diane E., Yang, Zheng, Wang, Haiqing, Murthy, Bindu

Get full text

The Effect of Renal Impairment on Single-Dose Pharmacokinetics of Daclatasvir, an HCV NS5A Inhibitor: 582 by Garimella, Tushar, Wang, Reena, Luo, Wen-Lin, Hwang, Carey, Sherman, Diane, Kandoussi, Hamza, Marbury, Thomas, Alcorn, Harry, Bertz, Richard, Bifano, Marc

Get full text

1166Evaluation of Drug-Drug Interaction between Daclatasvir and Methadone or Buprenorphine/Naloxone by Garimella, Tushar, Wang, Reena, Luo, Wen-Lin, Wastall, Philip, Kandoussi, Hamza, Demicco, Michael, Bruce, Robert, Hwang, Carey, Bertz, Richard, Bifano, Marc

Get full text

Evaluation of drug‐drug interaction between daclatasvir and methadone or buprenorphine/naloxone by Garimella, Tushar, Wang, Reena, Luo, Wen‐Lin, Wastall, Philip, Kandoussi, Hamza, Demicco, Michael, Bruce, Douglas, Hwang, Carey, Bertz, Richard, Bifano, Marc

“…Introduction Daclatasvir (DCV) is a potent hepatitis C virus (HCV) NS5A replication complex inhibitor with pangenotypic (1–6) activity in vitro. Methadone…”
Get full text